The role of BAFF in autoimmune diseases

Japanese Journal of Clinical Immunology

Volumn 28, Issue 5, 2005, Pages 333-342

  Matsushita, Takashi ^a   Sato, Shinichi ^b  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

B cell homeostasis; BAFF; rheumatic disease; self reactive B cells

Indexed keywords

B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; MEMBRANE PROTEIN; TNFRSF13C PROTEIN, HUMAN; TNFSF13B PROTEIN, HUMAN; TNFSF13B PROTEIN, MOUSE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL; AUTOIMMUNE DISEASE; HUMAN; IMMUNOLOGY; MOUSE; PHYSIOLOGY; REVIEW;

ANIMALS; AUTOIMMUNE DISEASES; B-CELL ACTIVATING FACTOR; B-CELL ACTIVATION FACTOR RECEPTOR; HUMANS; MEMBRANE PROTEINS; MICE; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33644693521     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.28.333     Document Type: Article

References (64)

1. Moore P. A., Belvedere O., Orr A., et al.: BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285: 260–263, 1999.
2. Schneider P., MacKay F., Steiner V., et al.: BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189: 1747–1756, 1999.
3. Shu H. B., Hu W. H., Johnson H: TALL-1 is a novel member of the TNF family that is downregulated by mitogens. J Leukoc Biol 65: 680–683, 1999.
4. Litinskiy M. B., Nardelli B., Hilbert D. M., et al.: DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 3: 822–829, 2002.
5. Nardelli B., Belvedere O., Roschke V., et al.: Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 97: 198–204, 2001.
6. Hanada T., Yoshida H., Kato S., et al.: Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity 19: 437–450, 2003.
7. Oren D. A., Li Y., Volovik Y., et al.: Structural basis of BLyS receptor recognition. Nat Struct Biol 9: 288–292, 2002.
8. Karpusas M., Cachero T. G., Qian F., et al.: Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes. J Mol Biol 315: 1145–1154, 2002.
9. Liu Y., Xu L., Opalka N., et al.: Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands. Cell 108: 383–394, 2002.
10. Gavin A. L., Ait-Azzouzene D., Ware C. F., et al.: DeltaBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF. J Biol Chem 278: 38220–38228, 2003.
11. Hahne M., Kataoka T., Schroter M., et al.: APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 188: 1185–1190, 1998.
12. Kelly K., Manos E., Jensen G., et al.: APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death. Cancer Res 60: 1021–1027, 2000.
13. Lopez-Fraga M., Fernandez R., Albar J. P., et al.: Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep 2: 945–951, 2001.
14. Roschke V., Sosnovtseva S., Ward C. D., et al.: BLyS and APRIL form biologically active het-erotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 169: 4314–4321, 2002.
15. Pradet-Balade B., Medema J. P., Lopez-Fraga M., et al.: An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein. Embo J 21: 5711–5720, 2002.
16. Mackay F., Browning JL: BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2: 465–475, 2002.
17. Hymowitz S. G., Patel D. R., Wallweber H. J., et al.: Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding. J Biol Chem 280: 7218–7227, 2005.
18. Patel D. R., Wallweber H. J., Yin J., et al.: Engineering an APRIL-specific B cell maturation antigen. J Biol Chem 279: 16727–16735, 2004.
19. Pelletier M., Thompson J. S., Qian F., et al.: Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF. J Biol Chem 278: 33127–33133, 2003.
20. Thompson J. S., Bixler S. A., Qian F., et al.: BAFF-R, a newly identified TNF receptor that specifi-cally interacts with BAFF. Science 293: 2108–2111, 2001.
21. Yan M., Brady J. R., Chan B., et al.: Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol 11: 1547–1552, 2001.
22. Ingold K., Zumsteg A., Tardivel A., et al.: Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 201: 1375–1383, 2005.
23. Schneider P: The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 17: 282–289, 2005.
24. Jelinek D. F., Darce J.R. Human B., lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors. Curr Dir Autoim-mun 8: 266–288, 2005.
25. Kayagaki N., Yan M., Seshasayee D., et al.: BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 17: 515–524, 2002.
26. Mackay F., Woodcock S. A., Lawton P., et al.: Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190: 1697–1710, 1999.
27. Tardivel A., Tinel A., Lens S., et al.: The anti-apoptotic factor Bcl-2 can functionally substitute for the B cell survival but not for the marginal zone B cell differentiation activity of BAFF. Eur J Immunol 34: 509–518, 2004.
28. Shulga-Morskaya S., Dobles M., Walsh M. E., et al.: B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J Immunol 173: 2331–2341, 2004.
29. Sasaki Y., Casola S., Kutok J. L., et al.: TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol 173: 2245–2252, 2004.
30. Amanna I. J., Dingwall J. P., Hayes CE: Enforced bcl-xL gene expression restored splenic B lymphocyte development in BAFF-R mutant mice. J Immunol 170: 4593–4600, 2003.
31. O'Connor B. P., Raman V. S., Erickson L. D., et al.: BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 199: 91–98, 2004.
32. Tsokos G. C., Fleming SD: Autoimmunity, complement activation, tissue injury and reciprocal Effects. Curr Dir Autoimmun 7: 149–164, 2004.
33. Sato S., Hasegawa M., Fujimoto M., et al.: Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 165: 6635–6643, 2000.
34. Hase H., Kanno Y., Kojima M., et al.: BAFF/ BLyS can potentiate B-cell selection with the B-cell coreceptor complex. Blood 103: 2257–2265, 2004.
35. Gorelik L., Cutler A. H., Thill G., et al.: Cutting edge: BAFF regulates CD21/35 and CD23 expression independent of its B cell survival function. J Immunol 172: 762–766, 2004.
36. Vora K. A., Wang L. C., Rao S. P., et al.: Cutting edge: germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function. J Immunol 171: 547–551, 2003.
37. Balazs M., Martin F., Zhou T., et al.: Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity 17: 341–352, 2002.
38. Do R. K., Hatada E., Lee H., et al.: Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 192: 953–964, 2000.
39. Ye Q., Wang L., Wells A. D., et al.: BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses. Eur J Immunol 34: 2750–2759, 2004.
40. Ng L. G., Mackay C. R., Mackay F: The BAFF/ APRIL system: life beyond B lymphocytes. Mol Immunol 42: 763–772, 2005.
41. Gross J. A., Johnston J., Mudri S., et al.: TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404: 995–999, 2000.
42. Khare S. D., Sarosi I., Xia X. Z., et al.: Severe B cell hyperplasia and autoimmune disease in TALL- 1 transgenic mice. Proc Natl Acad Sci U S A 97: 3370–3375, 2000.
43. Yan M., Wang H., Chan B., et al.: Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol 2: 638–643, 2001.
44. Lesley R., Xu Y., Kalled S. L., et al.: Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 20: 441–453, 2004.
45. Thien M., Phan T. G., Gardam S., et al.: Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20: 785–798, 2004.
46. Cheema G. S., Roschke V., Hilbert D. M., et al.: Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44: 1313–1319, 2001.
47. Zhang J., Roschke V., Baker K. P., et al.: Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166: 6–10, 2001.
48. Stohl W., Metyas S., Tan S. M., et al.: B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 48: 3475–3486, 2003.
49. Stohl W., Metyas S., Tan S. M., et al.: Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 63: 1096–1103, 2004.
50. Groom J., Kalled S. L., Cutler A. H., et al.: Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 109: 59–68, 2002.
51. Mariette X., Roux S., Zhang J., et al.: The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis 62: 168–171, 2003.
52. Pers J. O., d'Arbonneau F., Devauchelle-Pensec V., et al.: Is periodontal disease mediated by salivary baff in sjogren's syndrome? Arthritis Rheum 52: 2411–2414, 2005.
53. Wang H., Marsters S. A., Baker T., et al.: TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol 2: 632–637, 2001.
54. Sato S., Fujimoto M., Hasegawa M., et al.: Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 41: 1123–1133, 2004.
55. Matsushita T., Hasegawa M., Yanaba K., et al.: Elevated Serum BAFF Levels in Patients with Systemic Sclerosis (SSc): Enhanced BAFF Signaling in SSc B Lymphocytes. Arthritis Rheum: in press.
56. Saito E., Fujimoto M., Hasegawa M., et al.: CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 109: 1453–1462, 2002.
57. Krumbholz M., Theil D., Derfuss T., et al.: BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 201: 195–200, 2005.
58. Magliozzi R., Columba-Cabezas S., Serafini B., et al.: Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 148: 11–23, 2004.
59. Kalled S.L.: The role of BAFF in immune function and implications for autoimmunity. Immunol Rev 204: 43–54, 2005.
60. Castigli E., Wilson S. A., Scott S., et al.: TACI and BAFF-R mediate isotype switching in B cells. J Exp Med 201: 35–39, 2005.
61. Salzer U., Chapel H. M., Webster A. D., et al.: Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 37: 820–828, 2005.
62. Baker K. P., Edwards B. M., Main S. H., et al.: Generation and characterization of Lym-phoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 48: 3253–3265, 2003.
63. Furie R., Stohl W., Ginzler E., et al.: Safety, pharmacokinetic and pharmacodynamic results of a phase 1 single and double dose-escalation study of LymphoStat-B (human monoclonal antibody to BLyS) in SLE patients. Arthritis Rheum 48 (Suppl.): S377, 2003.
64. Stohl W: BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists. Curr Dir Autoimmun 8:289–304, 2005.